Welcome to our dedicated page for Cintas SEC filings (Ticker: CTAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cintas Corporation’s fleet of service trucks isn’t the only place routine meets precision. Each quarter the company behind millions of rented uniforms and facility-service deliveries files detailed disclosures that map recurring revenue, route density, and safety-product growth. If you are searching for “Cintas insider trading Form 4 transactions� or need the “Cintas quarterly earnings report 10-Q filing,� this page brings everything together.
Stock Titan layers AI on top of every submission to EDGAR. Our engine translates dense sections on segment margins or wash-plant capital spending into clear language, giving you “Cintas SEC filings explained simply.� Whether it’s a sudden 8-K about an acquisition or the annual report you have bookmarked as “Cintas annual report 10-K simplified,� the platform supplies:
- Instant alerts for “Cintas Form 4 insider transactions real-time� and “Cintas executive stock transactions Form 4.�
- Concise “Cintas earnings report filing analysis� highlighting uniform rental revenue, facility services profit, and cash-flow trends.
- Guided tools for “understanding Cintas SEC documents with AI,� including footnote roll-ups and risk-factor summaries.
- Keyword navigation across the “Cintas proxy statement executive compensation� to spot incentive-plan shifts.
- Context boxes that make “Cintas 8-K material events explained� in minutes, not hours.
Analysts monitor insider purchases before route expansions; portfolio managers compare quarter-over-quarter margin movement; corporate teams track fire-protection acquisitions. Whatever your role, you receive real-time filing updates, AI-powered summaries, and historical depth across every form—from 10-K and 10-Q to S-8 and 424B. Skip page-count fatigue and focus on decisions; we’ve already mined the documents for what matters.
Cintas Corp. (CTAS) filed a Form 144 indicating an insider’s intent to sell up to 5,084 common shares through broker Fifth Third Securities on or after 30 Jul 2025 via NASDAQ. The proposed sale carries an aggregate market value of $1.132 million and represents roughly 0.0013 % of the company’s 403.8 million shares outstanding.
The shares were originally acquired as a stock award on 17 Oct 2014. The filer reports no other sales in the past three months. Form 144 is a notice only; execution is not guaranteed, and no new operational or financial information was disclosed.
Graphjet Technology (Nasdaq: GTI) filed an 8-K to disclose that its Extraordinary General Meeting (EGM), originally set for 30 Jul 2025, has been adjourned before convening and will reconvene on 1 Aug 2025 at 9:00 a.m. ET.
The company says the sole purpose of the two-day delay is to give shareholders extra time to vote on the proposals outlined in the definitive proxy filed 11 Jul 2025. No changes were made to the record date (3 Jul 2025), agenda items or proxy materials. Previously submitted proxies remain valid unless shareholders choose to revise them.
The filing contains no financial results or transactional details. However, brief forward-looking statements highlight risks around capital needs, commercialization progress, Nasdaq listing compliance and market conditions.
Materiality: The adjournment is a procedural move; it may indicate insufficient votes so far, but it does not alter the company’s operations, capital structure or guidance.
Digimarc Corporation (DMRC) filed an 8-K announcing a Cooperation Agreement with activist investor Altai Capital Management and its principal, Rishi Bajaj. Effective 28-Jul-2025, the Board expanded from seven to eight directors and appointed Bajaj to fill the new seat until the 2026 annual meeting. In exchange, the Investors agreed to a stand-still period that lasts until the first day after the 2026 AGM: they will vote all DMRC shares they control in line with Board recommendations, except where both ISS and Glass Lewis advise otherwise or in an Extraordinary Transaction. The pact also contains customary non-disparagement, confidentiality and solicitation restrictions.
Bajaj will receive DMRC’s standard non-employee director compensation and an indemnification agreement; no related-party transactions or family relationships were disclosed. A press release (Ex. 99.1) announcing the agreement and appointment was issued on 29-Jul-2025. The Cooperation Agreement itself is filed as Ex. 10.1.
Freshworks (FRSH) Q2-25 10-Q highlights: Revenue rose 17.5% YoY to $204.7 m, lifting 1H-25 sales to $401 m (+18.2%). Subscription & maintenance continue to drive >98% of top-line.
Gross profit expanded to $173.5 m (84.8% margin, +110 bp YoY) while operating expenses fell 4% on disciplined R&D and S&M spend. As a result, operating loss narrowed sharply to $8.7 m vs. $43.8 m LY; net loss improved to $1.7 m (-$0.01/sh) from $20.2 m (-$0.07/sh). Six-month net loss stands at $3.0 m vs. $43.5 m.
Cash from operations turned markedly positive at $116.6 m (1H-24: $77.0 m). Even after $226.7 m of share repurchases (14.9 m shares at avg $15.11), liquidity remains strong with $859 m in cash & marketable securities and no debt. Deferred revenue grew 4.9% to $339.2 m; RPO totals $568.9 m, with 73% recognizable in the next 12 months.
The company continues to invest in product (capitalized software +$9.2 m YTD) and carries $147 m goodwill from the 2024 Device42 buy. Stock-based compensation remains elevated at $101 m YTD (25% of revenue). Share-count dilution slowed due to buybacks; 292 m shares outstanding at June-25.
Key watch-points: path to sustainable GAAP profitability, impact of continued repurchases on cash, and integration synergies from Device42.
Aclaris Therapeutics (Nasdaq: ACRS) has filed a Form 8-K to inform investors that it will host a conference call on 29 Jul 2025 to review top-line data from its Phase 2a study of ATI-2138, an oral covalent ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis. Two items are furnished: Exhibit 99.1 (investor presentation) and Exhibit 99.2 (press release). Under Reg FD, Items 7.01 and 8.01 are furnished—not filed—so the information is not subject to Exchange Act liability nor automatically incorporated into other SEC reports.
The 8-K contains no numerical efficacy, safety, or financial metrics. Investors must consult the accompanying exhibits or join the conference call for detailed results. No changes to financial statements or previously issued guidance are included.
FiEE, Inc. (Nasdaq: FIEE) filed a Form 10-Q/A for the quarter ended 30 Jun 24 to restate financials after discovering material errors in outstanding share counts and EPS. FY-23 shares are revised to 2.79 M (was 2.63 M) and Q2-24 shares to 2.97 M (was 2.81 M), lowering Q2-24 loss per share to $0.16 from $0.17 and 1H-24 loss per share to $1.27 from $1.34.
Operations. Net sales in Q2-24 were $0 versus $7.2 M YoY; gross profit nil. Operating loss narrowed to $0.49 M (Q2-23: $5.46 M) as expenses were cut and $0.16 M of vendor-liability forgiveness was booked. 1H-24 operating loss totals $3.76 M.
Balance sheet. Assets collapsed to $0.95 M from $12.36 M at 31 Dec 23 after receivables and inventories were written down. Cash is $0.63 M. Liabilities fell to $1.36 M, but equity turned to a $0.40 M deficit. A March 2024 issuance of 2 M preferred shares injected $1.36 M and generated a $1.44 M warrant value.
Governance. The amendment re-files CEO/CFO SOX certifications (Exhibits 31 & 32) and updated XBRL. Management states no other sections were updated and prior Q2-24 statements should not be relied upon.
Investor focus:
- Control weakness signaled by restatement.
- Revenue collapse and limited liquidity.
- Negative equity and ongoing losses.
- Preferred financing provides short-term cash but dilutes common holders.
Cintas Corp. (CTAS) Form 144 reveals a proposed insider sale of 17,301 common shares, about 0.004 % of the company’s 403.8 M shares outstanding. At the recent market price, the block is valued near $3.84 million. The shares were obtained the same day via a cash-settled stock-option exercise and will be sold through Fidelity Brokerage Services on or around 28 Jul 2025 on Nasdaq. No other insider sales during the past three months are reported, and the filer attests to possessing no undisclosed adverse information.
EastGroup Properties (EGP) Q2-25 10-Q highlights: Rental revenues rose 11.5% YoY to $177.3 m and six-month revenues climbed 12.3% to $351.7 m. Net income for the quarter increased 14.5% to $63.3 m ($1.20 diluted EPS), while year-to-date EPS of $2.35 was essentially flat because the prior-year period included an $8.8 m property-sale gain. Same-property NOI advanced 5.9% YTD. New and renewal leases achieved +45.8% cash rent spreads, reflecting strong industrial demand.
The operating portfolio was 97.1% leased and 96.0% occupied at 30-Jun; only 4.6% of annualised base rent expires in 2H-25. Operating cash flow increased 15.6% to $277.1 m and funded $207.9 m of development, improvements and land purchases. Unsecured borrowings fell to $1.46 bn after repayment of a $50 m loan and refinancing of a $100 m term loan at an effective 4.97% rate; Moody’s affirmed the Baa2 rating and lifted the outlook to positive.
Equity issuance provided $148 m YTD and a further $117 m post-quarter, supporting an 18-project (3.7 m sq ft) development pipeline that is 16% pre-leased and budgeted at $531 m. Quarterly dividends of $1.40/sh were declared. Comprehensive income was trimmed by an $11.1 m unrealised loss on interest-rate swaps. Subsequent events include the $61.4 m purchase of two Raleigh distribution buildings (318 k sq ft) and an $8.5 m Orlando land acquisition (37 acres).